Immune Thrombocytopenia
We recommend
Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment – Case Study
In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize platelet count can be through administering a thrombopoietin receptor agonist (TPO-RA). The following case study presents a successful treatment of newly diagnosed ITP.
Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Immune thrombocytopenic purpura, or immune thrombocytopenia (ITP), typically manifests as bleeding…
Romiplostim Before Splenectomy in a Patient with ITP - Case Report
In the following case report from authors at a university hospital in Barcelona, the successful use…
Articles on this topic
Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
This case report from the United States features an ideal therapeutic response to romiplostim…
ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
There can be numerous causes of newly acquired immune thrombocytopenia (ITP), often being…
Romiplostim in a Pregnant Woman − Case Report
The following clinical case demonstrates good control of resistant immune thrombocytopenia in…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- ITP with Severe Hemorrhagic Manifestations Associated with COVID-19 – Case Study
- Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment – Case Study
- Romiplostim Before Splenectomy in a Patient with ITP - Case Report
- Romiplostim in a Pregnant Woman − Case Report
- Effect of Romiplostim in Refractory ITP with Possibility of Maintaining Response Without Treatment – Case Report
- Romiplostim in Life-Threatening Bleeding Situations − Case Reports
Journal on this topic
Related topic